Morizane, Chigusa
Ueno, Makoto
Ikeda, Masafumi
Sudo, Kentaro
Hirashima, Yoshinori
Kuroda, Masataka
Ueno, Shinji
Okusaka, Takuji
Furuse, Junji
Article History
Received: 8 December 2023
Revised: 8 December 2023
Accepted: 15 December 2023
First Online: 23 January 2024
Competing interests
: CM received grants from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck biopharma, Daiichi Sankyo, Hitachi, and Boehringer Ingelheim. The author received consulting fees from Yakult Honsha, MSD K.K., Servier, Boehringer Ingelheim, Taiho. The author also received payment for lectures and presentations from Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai, MSD K.K., and AstraZeneca. MU received grants and contracts from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, MSD, Astellas Pharma, Eisai, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, DFP, Daiichi Sankyo, Novartis, Boehringer Ingelheim, J-pharma. The author also received payment for lectures and presentations from Taiho Pharmaceutical, AstraZeneca, Yakult Honsha, MSD, Nihon Servier, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, Boehringer Ingelheim, and J-pharma. MI received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Chiome Bioscience, Chugai, Eisai, Eli Lilly Japan, Delta-Fly Pharma, Invitae, J-Pharma, Merck biopharma, Merus N.V., MSD, Novartis, Nihon Servier, Ono Pharmaceutical, Pfizer, Syneos Health, Takeda, Yakult. The author received honoraria from AstraZeneca, AbbVie, Abbott Japan, Bayer, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly Japan, EA Pharma, Fujifilm Toyama Chemical, Incyte Biosciences Japan, MSD, Nihon Servier, Nippon Kayaku, Novartis, Otsuka, Teijin, Taiho, Taisho Pharmaceutical, Takeda, and Yakult. KS received institute research funding from Bristol-Myers Squibb/Ono Pharmaceutical; received grants or contracts from Eisai and Incyte. The author also received honoraria from Yakult Honsha, Ono Pharmaceutical, and Novartis Pharmaceuticals. YH, MK, and SU are employees at Ono Pharmaceutical Co., Ltd. TO received grants from AstraZeneca, Syneos Health, EP clude, Eisai, MSD, and Insight Japan; received consulting fees from AstraZeneca, Eisai, Nihon Servier, Dainippon, Sumitomo Pharma, Bristol-Myers, FUJIFILM Toyama Chemical. The author also received payment or honoraria for lectures and presentations from AstraZeneca, Insight Japan, Eisai, Ono Pharmaceutical, Yakult Honsha, Johnson & Johnson, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Nihon Servier, Nippon Shinyaku, Eli Lilly Japan, Pfizer Japan, and Novartis Pharmaceuticals. JF received funding from Ono Pharmaceutical; received grants or contracts from Astellas, Astra Zeneca, Incyte Biosciences Japan, Eisai, MSD, Ono Pharmaceutical, Sanofy, J-Pharma, Daiichi Sankyo, Sumitomo Dainippon, Taiho Pharmaceutical, Takeda, Delta-Fly-Pharma, and Chugai Pharma. The author received consulting fees from Fuji film, Astellas, Onco Therapy Science, Delta-Fly-Pharma, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, AstraZeneca, Incyte Biosciences Japan, and J-Pharma. The author also received payment or honoraria for lectures and presentations from Ono Pharmaceutical, Chugai Pharma, Incyte Biosciences Japan, Eisai, Eli Lilly Japan, AstraZeneca, Yakult Honsha, Servier Japan, MSD, Novartis Pharma, Takeda, Bayer, Taiho Pharmaceutical, EA Pharma, Teijin pharma, Daiichi Sankyo, and Terumo. The author participated on a Data Safety Monitoring Board or Advisory Board at Onco Therapy Science, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Merck Bio, MSD, and Taiho Pharmaceutical. The author is in a leadership role or part of a committee at Japan Oncology Network in Hepatobiliary and Pancreas.
: The study (JapicCTI-184230) was conducted in compliance with the protocol, the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines, and other applicable laws and regulations. It was also approved by the Institutional Review Board of each study site. All participants gave their written informed consent for study participation.